NCT01372176

Brief Summary

An increasing number of patients survive critical illness and intensive care, but describe having impaired physical function several years after discharge as a consequence of extensive loss of muscle mass. Reasons for loss of muscle mass and physical function are multiple, but insufficient nutrition is likely to contribute. This randomised trial will investigate the effect of an optimised nutrition therapy during intensive care, on short term clinical outcome and physical quality of life. We hypothesise, that early nutritional therapy, directed towards patient-specific goals for energy and protein requirements, will improve both short- and long-term outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
203

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jun 2013

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 6, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 13, 2011

Completed
2 years until next milestone

Study Start

First participant enrolled

June 1, 2013

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

January 5, 2017

Status Verified

January 1, 2017

Enrollment Period

3.4 years

First QC Date

June 6, 2011

Last Update Submit

January 4, 2017

Conditions

Keywords

Intensive care unitCritical illnessMortalityReduced quality of lifeLoss of lean body massLoss of physical functionOptimised nutritional supportEarly initiation of nutritionIndirect calorimetry

Outcome Measures

Primary Outcomes (1)

  • Physical function

    Physical function 6 months after randomisation (physical component summary (PCS)-score of SF-36, conducted as phone-interview by a person blinded to the intervention

    6 months after randomisation

Secondary Outcomes (17)

  • Mortality

    28 days

  • Mortality

    90 days

  • Mortality

    6 months

  • Survival status for all patients

    6 months

  • New organ failure in the ICU

    Followed until ICU discharge, an expected average of 21 days

  • +12 more secondary outcomes

Study Arms (2)

Early Goal-Directed Nutrition

EXPERIMENTAL
Other: Early Goal-Directed Nutrition

ASPEN-guidelines

ACTIVE COMPARATOR
Other: ASPEN-guidelines

Interventions

1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission). 2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy. 3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN).

Early Goal-Directed Nutrition

EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.

ASPEN-guidelines

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Acutely admitted to the ICU
  • Expected length of stay in ICU \> 3 days
  • Mechanically ventilated, which enables indirect calorimetry
  • Have central venous catheter wherein TPN can be administered
  • Written proxy consent obtained (proxy consent defined as consent from two doctors, who are independent of the trial)
  • Must be able to understand Danish

You may not qualify if:

  • Contraindications to use enteral nutrition
  • Contraindications to use parenteral nutrition, eg. hypersensitivity towards fish-, egg or peanut protein, or any of the active substances in the PN products
  • Receiving a special diet
  • Burns \> 10% total body surface area
  • Severe hepatic failure (Child-Pugh class C) or severe hepatic dysfunction: Bilirubin ≥ 50 µmol/l (3 mg/dl) + alanine aminotransferase ≥ 3 times upper reference value
  • Traumatic brain injury
  • Diabetic ketoacidosis
  • Hyperosmolar non-ketotic acidosis
  • Known or suspected hyperlipidemia
  • BMI below 17 or severe malnutrition
  • Pregnancy
  • The clinician finds that the patient is too deranged (circulation, respiration, electrolytes etc.) or that death is imminent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Intensive Care, Rigshospitalet

Copenhagen, 2100, Denmark

Location

Related Publications (2)

  • Allingstrup MJ, Kondrup J, Wiis J, Claudius C, Pedersen UG, Hein-Rasmussen R, Bjerregaard MR, Steensen M, Jensen TH, Lange T, Madsen MB, Moller MH, Perner A. Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial. Intensive Care Med. 2017 Nov;43(11):1637-1647. doi: 10.1007/s00134-017-4880-3. Epub 2017 Sep 22.

  • Allingstrup MJ, Kondrup J, Wiis J, Claudius C, Pedersen UG, Hein-Rasmussen R, Jensen TH, Lange T, Perner A. Early goal-directed nutrition in ICU patients (EAT-ICU): protocol for a randomised trial. Dan Med J. 2016 Sep;63(9):A5271.

MeSH Terms

Conditions

Critical IllnessMuscular DiseasesMuscular Atrophy

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesNeuromuscular ManifestationsNeurologic ManifestationsAtrophyPathological Conditions, AnatomicalSigns and Symptoms

Study Officials

  • Anders Perner, Professor, MD, PhD

    Rigshospitalet, Department of Intensive Care

    PRINCIPAL INVESTIGATOR
  • Matilde Jo Allingstrup, PhD Fellow, MSc

    Rigshospitalet, Department of Intensive Care

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Fellow, MSc Clinical Nutrition

Study Record Dates

First Submitted

June 6, 2011

First Posted

June 13, 2011

Study Start

June 1, 2013

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

January 5, 2017

Record last verified: 2017-01

Locations